Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

DBCOND0155509Anatomical Structures and Fluids Cardiovascular Diseases

Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Classified under: Anatomical Structures and Fluids
Cardiovascular Diseases
Chemically-Induced Disorders
Hemic and Lymphatic Diseases
Immune System Diseases
Urogenital Diseases
Wounds and Injuries
Indicated drugs: Narsoplimab

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

2Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account